Back
EHRA Premium Access

Atrial high rate episodes increase the risk of ventricular arrhythmias and mortality in patients with implantable defibrillators and cardiac resynchronization devices.

Session: Poster session 3 - Ventricular Arrhythmias and SCD - Epidemiology, Prognosis, Outcome
Topic: Risk Factors and Risk Assessment
Speaker: Professor P. Vergara (Naples, IT)
Event: EHRA 2019

Congress Presentation

Add to my library

Like

About the speaker

Professor Pasquale Vergara

University of Naples Federico II, Naples (Italy)
0 follower

18 more presentations in this session

Association between ventricular fibrillation recurrences and chest compressions in out-of-hospital cardiac arrest

Speaker: Associate Professor F. Guerra (Ancona, IT)

Access
Abstract
Like
Thumbnail

Clinical impact on ventricular arrhythmic risk of serum free thyroxine concentration in euthyroid patients with structural heart diseases

Speaker: Associate Professor H. Makimoto (Shimotsuke, JP)

Access
Abstract
Like
Thumbnail

Precedent non-sustained ventricular tachycardias predicts subsequent ICD interventions and heart failure hospitalization in primary prevention ICD patients

Speaker: Associate Professor H. Makimoto (Shimotsuke, JP)

Access
Abstract
Like
Thumbnail

P-wave morphology and risk of sudden cardiac death in patients with coronary artery disease

Speaker: Doctor J. Perkiomaki (Oulu, FI)

Access
Abstract
Like
Thumbnail

10-year trends in the use of catheter ablation for the treatment ofVT versus other ablation procedures and PCI for the treatment of IHD

Speaker: Doctor R. Anderson (Toronto, CA)

Access
Abstract
Slides
Like
Thumbnail

Access the full session

Poster session 3 - Ventricular Arrhythmias and SCD - Epidemiology, Prognosis, Outcome

Speakers: Professor P. Vergara, Associate Professor F. Guerra, Associate Professor H. Makimoto, Associate Professor H. Makimoto, Doctor J. Perkiomaki...
Access
Like
Thumbnail

About the event

Image

EHRA 2019

17 March - 19 March 2019

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

bristol-myers-squibb Explore sponsored resources
novartis Explore sponsored resources